Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,166,820 papers from all fields of science
Search
Sign In
Create Free Account
CGP 69846A
Known as:
CGP69846A
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
ISIS 5132
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Cellular pharmacology of antisense oligodeoxynucleotides.
C. Schumacher
Methods in Enzymology
2000
Corpus ID: 34308612
1999
1999
Distribution of a 20-Mer Phosphorothioate Oligonucleotide, CGP69846A (ISIS 5132), into Airway Leukocytes and Epithelial Cells Following Intratracheal Delivery to Brown-Norway Rats
H. Danahay
,
J. Giddings
,
R. Christian
,
H. Moser
,
J. Phillips
Pharmaceutical Research
1999
Corpus ID: 25119765
AbstractPurpose. To evaluate the pulmonary distribution of CGP69846A (ISIS 5132), a phosphorothioate oligonucleotide, following…
Expand
1998
1998
Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications.
C. Schumacher
,
C. Cioffi
,
H. Sharif
,
W. Haston
,
B. Monia
,
L. Wennogle
Molecular Pharmacology
1998
Corpus ID: 11108408
To characterize the pharmacodynamic properties of CGP 69846A/ISIS 5132, an antisense oligodeoxynucleotide directed against the…
Expand
Highly Cited
1997
Highly Cited
1997
Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
T. Geiger
,
M. Müller
,
B. Monia
,
D. Fabbro
Clinical Cancer Research
1997
Corpus ID: 6819896
A 20-mer phosphorothioate oligodeoxynucleotide (ODN) directed against human C-raf kinase (CGP 69846A or ISIS 5132) was analyzed…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE